MX2017016681A - Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. - Google Patents

Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Info

Publication number
MX2017016681A
MX2017016681A MX2017016681A MX2017016681A MX2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A
Authority
MX
Mexico
Prior art keywords
chloroquine
treatment
inflammatory
clemizole
cancerous conditions
Prior art date
Application number
MX2017016681A
Other languages
English (en)
Inventor
S Glenn Jeffrey
A Pham Edward
Original Assignee
Eiger Group Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group Int Inc filed Critical Eiger Group Int Inc
Publication of MX2017016681A publication Critical patent/MX2017016681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se describen en la presente métodos para uso de R-cloroquina o clemizol o combinaciones de R-cloroquina y clemizol para el tratamiento de un sujeto que necesita del mismo. Los métodos incluyen métodos de tratamiento de afecciones inflamatorias, tratamiento de cáncer hepático o reducción del riesgo de desarrollar cáncer hepático en un sujeto. Los usos también incluyen métodos de tratamiento de esteatohepatitis no alcohólica en un sujeto.
MX2017016681A 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. MX2017016681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Publications (1)

Publication Number Publication Date
MX2017016681A true MX2017016681A (es) 2018-07-06

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017016681A MX2017016681A (es) 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2022008100A MX2022008100A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022008100A MX2022008100A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Country Status (13)

Country Link
US (2) US10688083B2 (es)
EP (1) EP3317274A4 (es)
JP (2) JP7068827B2 (es)
KR (2) KR20180032578A (es)
CN (2) CN113274386A (es)
AU (3) AU2016288699B2 (es)
CA (2) CA3178499A1 (es)
HK (1) HK1249508A1 (es)
IL (4) IL300476B1 (es)
MX (3) MX2017016681A (es)
TW (3) TWI830262B (es)
WO (1) WO2017004454A1 (es)
ZA (1) ZA201708471B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300476B1 (en) 2015-06-30 2024-03-01 Eiger Group Int Inc Use of chloroquine and calamizole compounds to treat inflammatory and cancerous conditions
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
WO2019099706A1 (en) * 2017-11-15 2019-05-23 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN115515935A (zh) * 2020-04-30 2022-12-23 中美华世通生物医药科技(武汉)股份有限公司 冠状病毒感染的治疗或预防
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) * 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
US6572858B1 (en) * 1999-04-30 2003-06-03 Apt Pharmaceuticals, Llc Uses for anti-malarial therapeutic agents
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP1599212A4 (en) 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
EP1656124A1 (en) * 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0415935A (pt) 2003-10-27 2007-01-02 Vertex Pharma combinações para tratamento de hcv
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) * 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
MX2008010355A (es) 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS ASSOCIATED WITH SYNERGIC RESPONSES TO ONCOGENIC MUTATIONS
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
TWI574961B (zh) * 2009-05-27 2017-03-21 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
ES2738101T3 (es) * 2009-07-31 2020-01-20 Smc Global Asset Inc Ratón modelo de esteatohepatitis-cáncer de hígado
US9415046B2 (en) * 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
KR101974675B1 (ko) * 2011-09-16 2019-05-02 갈렉틴 테라퓨틱스, 인크. 비알콜성 지방간염 및 비알콜성 지방간 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물
CA2864389A1 (en) * 2012-02-20 2013-08-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
TW201402556A (zh) 2012-05-30 2014-01-16 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物或其鹽
WO2014031769A2 (en) * 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
CA2931458A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
IL300476B1 (en) 2015-06-30 2024-03-01 Eiger Group Int Inc Use of chloroquine and calamizole compounds to treat inflammatory and cancerous conditions

Also Published As

Publication number Publication date
BR112017028601A2 (pt) 2018-08-28
EP3317274A1 (en) 2018-05-09
US20210052553A1 (en) 2021-02-25
IL279020B1 (en) 2023-03-01
CA2989634A1 (en) 2017-01-05
KR20180032578A (ko) 2018-03-30
CA2989634C (en) 2022-12-06
EP3317274A4 (en) 2019-05-08
CN107922404A (zh) 2018-04-17
IL300476A (en) 2023-04-01
IL310969A (en) 2024-04-01
KR20230129590A (ko) 2023-09-08
HK1249508A1 (zh) 2018-11-02
JP7068827B2 (ja) 2022-05-17
AU2021201234A1 (en) 2021-03-11
AU2016288699B2 (en) 2020-11-26
JP7470151B2 (ja) 2024-04-17
MX2022008100A (es) 2022-07-11
CA3178499A1 (en) 2017-01-05
AU2023201397A1 (en) 2023-04-06
IL256233A (en) 2018-02-28
JP2022105149A (ja) 2022-07-12
CN107922404B (zh) 2021-06-29
TW201717941A (zh) 2017-06-01
IL279020A (es) 2020-12-31
TW202402283A (zh) 2024-01-16
NZ738291A (en) 2021-06-25
US10688083B2 (en) 2020-06-23
JP2018519340A (ja) 2018-07-19
IL279020B2 (en) 2023-07-01
ZA201708471B (en) 2022-05-25
TW202317103A (zh) 2023-05-01
MX2023003792A (es) 2023-04-26
US20180200228A1 (en) 2018-07-19
AU2016288699A1 (en) 2018-01-18
CN113274386A (zh) 2021-08-20
TWI771272B (zh) 2022-07-21
TWI830262B (zh) 2024-01-21
IL300476B1 (en) 2024-03-01
WO2017004454A1 (en) 2017-01-05
WO2017004454A8 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2022008100A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
IL276808A (en) Preparations and methods for the treatment of cancer
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
IL280830A (en) Bracelets for use in cancer treatment methods
WO2017059122A8 (en) Methods of treating and preventing amyotrophic lateral sclerosis
PH12016501838A1 (en) Compounds and their methods of use
IL272147A (en) Methods and preparations for the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
EP3781148A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
MX2019010060A (es) Composiciones y metodo para tratar cancer.
IL280262A (en) Compositions and methods for treating cancer